Clinical Trials Insight: 700028319

Trial Profile

Clinical Trials Insight: 700028319

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2008

At a glance

  • Drugs Interleukin-2; IPH 1101
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 23 May 2008 Results will be presented at the Gamma Delta T cell conference in Marseille according to an Innate Pharma media release.
    • 23 May 2008 Results have been reported in an Innate Pharma media release.
    • 23 May 2008 Primary efficacy endpoint not reached according to an Innate Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top